Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) – Stock analysts at Leerink Swann upped their Q4 2016 earnings per share (EPS) estimates for Sucampo Pharmaceuticals in a report issued on Wednesday. Leerink Swann analyst J. Gerberry now expects that the brokerage will earn $0.48 per share for the quarter, up from their previous forecast of $0.31. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2017 earnings at $1.72 EPS and FY2018 earnings at $1.71 EPS.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.26 by $0.02. The company earned $57.90 million during the quarter, compared to analysts’ expectations of $51.30 million. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. Sucampo Pharmaceuticals’s revenue for the quarter was up 73.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.16 earnings per share.

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Several other analysts also recently commented on the stock. Jefferies Group reissued a “hold” rating and set a $16.00 price objective (up from $14.00) on shares of Sucampo Pharmaceuticals in a research report on Friday. Vetr raised shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $14.00 price objective on the stock in a research report on Thursday, September 29th. Northland Securities initiated coverage on shares of Sucampo Pharmaceuticals in a report on Wednesday, September 7th. They set an “outperform” rating and a $15.00 price target on the stock. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 8th. Finally, Mizuho downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $13.00 price target on the stock. in a report on Thursday, August 4th. Five investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $16.78.

Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 15.20 on Monday. Sucampo Pharmaceuticals has a 52 week low of $9.59 and a 52 week high of $18.75. The stock has a market cap of $650.74 million, a PE ratio of 51.35 and a beta of 1.62. The company’s 50-day moving average is $12.64 and its 200 day moving average is $11.75.

Several institutional investors have recently modified their holdings of the company. LSV Asset Management boosted its position in shares of Sucampo Pharmaceuticals by 258.7% in the third quarter. LSV Asset Management now owns 1,730,916 shares of the biopharmaceutical company’s stock valued at $21,307,000 after buying an additional 1,248,389 shares during the period. BlackRock Fund Advisors boosted its stake in Sucampo Pharmaceuticals by 3.1% in the first quarter. BlackRock Fund Advisors now owns 1,630,036 shares of the biopharmaceutical company’s stock worth $17,816,000 after buying an additional 48,420 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Sucampo Pharmaceuticals by 3.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 675,955 shares of the biopharmaceutical company’s stock worth $8,321,000 after buying an additional 22,193 shares during the last quarter. Teachers Advisors LLC boosted its stake in Sucampo Pharmaceuticals by 5.3% in the third quarter. Teachers Advisors LLC now owns 502,729 shares of the biopharmaceutical company’s stock worth $6,189,000 after buying an additional 25,500 shares during the last quarter. Finally, Teachers Advisors Inc. boosted its stake in Sucampo Pharmaceuticals by 12.7% in the second quarter. Teachers Advisors Inc. now owns 477,229 shares of the biopharmaceutical company’s stock worth $5,235,000 after buying an additional 53,838 shares during the last quarter. Hedge funds and other institutional investors own 38.91% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

5 Day Chart for NASDAQ:SCMP

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.